Canada markets closed

Portage Biotech Inc. (PRTG)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
0.2500+0.0018 (+0.73%)
At close: 04:00PM EDT
0.2400 -0.01 (-4.00%)
After hours: 06:41PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.2482
Open0.2476
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.2351 - 0.2640
52 Week Range0.2000 - 3.9500
Volume79,488
Avg. Volume304,074
Market Cap4.946M
Beta (5Y Monthly)95.43
PE Ratio (TTM)N/A
EPS (TTM)-8.5200
Earnings DateJul 29, 2024 - Aug 02, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.00
  • GlobeNewswire

    Portage Biotech Announces Plans to Expand its Evaluation of Strategic Alternatives

    -Adenosine clinical development pausedWESTPORT, Conn., April 12, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today reported that it is expanding its evaluation of strategic alternatives and implementing additional measures to extend its available cash runway. After a review of the Company’s future funding needs for clinical development of its adenosine an

  • GlobeNewswire

    Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares

    Company generated approximately $2.8M of non-dilutive funding to extend cash runwayWESTPORT, Conn., March 26, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today reported that it has completed selling its equity holding in Intensity Therapeutics (NASDAQ: INTS). Portage was an early INTS investor and during the past few months, Portage has been able to monet

  • GlobeNewswire

    Portage Biotech Reports Results for Fiscal Quarter Ended December 31, 2023, and Business Update

    Company focused on adenosine platform clinical developmentWESTPORT, Conn., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today reported financial results for the fiscal quarter ended December 31, 2023. “The Company is focused on advancing its ADPORT-201 Phase 1a/1b clinical trial of PORT-6 (adenosine 2A inhibitor) and P